



YEARS OF TRUST & DEVOTION

PEOPLE TRUST US CONDENSED INTERIM FINANCIAL INFORMATION FOR THE HALF YEAR ENDED 31 DECEMBER 2024



TABLE OF **CONTENTS**

CORPORATE INFORMATION	03
DIRECTORS' REVIEW REPORT	04
DIRECTORS' REVIEW REPORT (URDU)	07
INDEPENDENT AUDITOR'S REVIEW REPORT	11
CONDENSED INTERIM UNCONSOLIDATED STATEMENT OF FINANCIAL POSITION	12
CONDENSED INTERIM UNCONSOLIDATED STATEMENT OF PROFIT OR LOSS	13
CONDENSED INTERIM UNCONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME	14
CONDENSED INTERIM UNCONSOLIDATED STATEMENT OF CHANGES IN EQUITY	15
CONDENSED INTERIM UNCONSOLIDATED STATEMENT OF CASH FLOWS	16
NOTES TO THE CONDENSED INTERIM UNCONSOLIDATED FINANCIAL STATEMENTS	17
CONDENSED INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION	34
CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS	35
CONDENSED INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME	36
CONDENSED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY	37
CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS	38
NOTES TO THE CONDENSED INTERIM CONSOLIDATED	39



CORPORATE INFORMATION

BOARD OF DIRECTORS

Mrs. Akhter Khalid Waheed Mr. Osman Khalid Waheed Mrs. Amna Piracha Khan Mrs. Munize Azhar Peracha Mr. Shahid Anwar

Mr. Arshad Saeed Husain

Mr. Suleman Ghani

Non-Executive Director **Executive Director** Non-Executive Director Non-Executive Director Non-Executive Director Independent Director Independent Director

Chairperson Chief Executive Officer

AUDIT COMMITTEE

Mr. Arshad Saeed Husain Mrs. Amna Piracha Khan Mr. Shahid Anwar Mr. Suleman Ghani

Chairman Member Member Member

INVESTMENT COMMITTEE

Mr. Suleman Ghani Mr. Osman Khalid Waheed Mr. Shahid Anwar

Chairman Member Member

HR & REMUNERATION COMMITTEE

Mr. Arshad Saeed Husain Mr. Osman Khalid Waheed Mrs. Munize Azhar Peracha Mr. Shahid Anwar

Chairman Member Member Member

COMPANY SECRETARY

Syed Ghausuddin Saif

LEGAL ADVISORS

Khan & Piracha

CHIEF FINANCIAL OFFICER

Mr. Muhammad Farhan Rafiq

SHARE REGISTRAR

CorpTec Associates (Pvt.) Limited 503-E, Johar Town, Lahore, Pakistan Telephone: +92-42-35170336-37 Fax: +92-42-35170338

HEAD OF INTERNAL AUDIT

Mr. Rizwan Hameed Butt

FACTORY

P.O. Ferozsons, Amangarh Nowshera (KPK), Pakistan Telephone: +92-923-614295, 610159 Fax: +92-923-611302

EXTERNAL AUDITORS

KPMG Taseer Hadi & Co. **Chartered Accountants**

HEAD OFFICE

5 K.M - Sunder Raiwind Road Lahore, Pakistan Telephone: +92-42-36026700 Fax: +92-42-36026701

INTERNAL AUDITORS

EY Ford Rhodes **Chartered Accountants**

BANKERS

Allied Bank Limited Bank Alfalah Limited Bank Al-Habib Limited Bank of Punjab - Taqwa BankIslami Pakistan Limited Faysal Bank Limited First Habib Modaraba Habib Bank Limited Habib Metropolitan Bank Limited MCB Bank Limited Meezan Bank Limited

SALES OFFICE, LAHORE

43-Al Noor Building, Bank Square The Mall, Lahore, Pakistan Telephone: +92-42-37358194 Fax: +92-42-37313680

REGISTERED OFFICE

197-A, The Mall, Rawalpindi, Pakistan Telephone: +92-51-4252155-57 Fax: +92-51-4252153 Email: cs@ferozsons-labs.com

SALES OFFICE, KARACHI

House No. 9, Block 7/8, Maqbool Cooperative Housing Society, Shahrah-e-Faisal, Karachi, Pakistan Telephone: +92-21-34386852 Fax: +92-21-34386754

DIRECTORS' REVIEW REPORT ON CONDENSED **INTERIM FINANCIAL INFORMATION FOR THE SIX** MONTHS ENDED 31 DECEMBER 2024

We are pleased to present a brief review of the Company's un-audited Standalone and Consolidated condensed interim financial information for the half year ended 31 December 2024. The consolidated condensed interim financial information incorporates the Company's 98% owned venture Farmacia and subsidiary BF Biosciences Limited.

Highlights of the Company's Standalone and Consolidated Financial Results

A summary of operating results for the period is given below:

	Stand	lalone		Conso	lidated	
6 Months 31-Dec-24	6 Months 31-Dec-23		1			

(Rupees in thousands)

Revenue - net	7,032,685	6,710,878	3,676,106	3,087,911	9,259,937	8,298,818	4,730,951	3,870,277
Gross profit	2,766,703	2,490,130	1,459,865	1,152,836	3,942,718	3,194,276	2,089,716	1,474,929
Profit before tax	413,590	377,971	215,098	74,343	687,799	604,658	327,377	138,444
Profit after tax	252,326	257,054	111,815	76,538	418,571	393,099	177,551	111,630
Earnings per share	5.80	5.91	2.57	1.76	8.53	8.40	3.46	2.34

Financial and Operational Review of Ferozsons Laboratories Limited

The Company's consolidated net sales closed at Rs. 9,260 million, depicting a growth of 12% over the same period last year. On a standalone basis, the Company's net sales closed at Rs. 7,033 million, with a growth of 5% over the same period last year.

In-market generic sales increased by 25% whereas institutional sales of generics and medical devices declined by 24%. The decline in institutional sales is primarily due to medical devices tenders supplied in the same period last year.

The Company's Gross Profit (GP) margin currently stands at 39% compared to 37% during the same period last year. The increase in GP margin primarily reflects change in sales mix along with price increase.

Selling and distribution expenses have been increased by 7% whereas administrative expenses have increased by 18% mainly due to inflationary impact.

Profit from operations grew by 23% while profit after tax decreased by 2%. The decline in profit after tax is mainly attributable to higher finance costs and taxation expenses during the period under review.

Finance costs have increased by 53% mainly due to increase in trade debts along with delays in settlement by the government institutions as cash flow gaps are managed through running finance facilities. These trade debts mainly consist of receivables from government institutions against supplies of medical devices tenders and the Company is actively engaging with these institutions for earliest settlement.

The effective tax rate has closed at 39% compared to 32% during the same period last year mainly due to change in tax regime for export sales by the federal government.

DIRECTORS' REVIEW REPORT ON CONDENSED **INTERIM FINANCIAL INFORMATION FOR THE SIX** MONTHS ENDED 31 DECEMBER 2024

The earnings per share (EPS) for the six months ended 31 December 2024 closed at Rs. 5.80, compared to Rs. 5.91 in the same period last year.

Financial and Operational Review of BF Biosciences Limited (Subsidiary Company)

The sales of the subsidiary Company, BF Biosciences Limited closed at Rs. 2,714 million, compared to Rs. 1,853 million, depicting a growth of 46% over the same period last year. The profit after tax of the Company closed at Rs. 196 million against Rs. 153 million achieved same period last year, depicting an increase of 28%. Based on the profit after tax and weighted average number of shares, the earnings per share (EPS) for the half year ended 31 December 2024 translates to Rs. 2.66 compared with Rs. 2.42 in the same period last year.

Future Outlook

During the second quarter under review, the State Bank of Pakistan reduced the monetary policy rates by 450 basis points. This is a welcoming step that will ultimately help to improve country's economic activity going forward. The reduction will also help the Company to curb rising pressure on its finance costs.

As of balance sheet date, we have approximately Rs. 2.3 billion receivables from Government Institutions. The majority of these receivables are outstanding since last one year and represent supplies made to different government institutions in good faith against tenders. The delay in the recovery of these receivables is unprecedented, and ultimately impacts the industry's ability to maintain further supplies to these institutions.

Acknowledgments

We want to acknowledge the consistent efforts and dedication of our employees towards achievement of the Company's objectives. We also thank our principals, business partners and valued customers for their continuous support and confidence in the Company.

For and on behalf of the Board of Directors

Mr. Osman Khalid Waheed Chief Executive Officer

Mrs. Akhter Khalid Waheed Chairperson

28 February 2025

نی ایف بائیو سائنسز لمییند (و ملی سمینی) کا مالیاتی اور آیریشنل حائزه:

زیلی کمپنی، بی ایف بائیوسائنسز لمیٹڈ کی فروخت 2,714ملین روپے رہی، جو پچھلے سال کی اس مدت میں 1,853 ملین روپے کے مقابلے میں 46% کا اضافہ ظاہر کرتی ہے۔ ممپنی کا بعد از کمیں منافع 196 ملین رویے رہا، جبجہ پچھلے سال کی اس مدت میں یہ 153 ملین رویے تھا، جو 28% کا اضافہ ہے۔ میں کے بعد منافع اور Weighted Average Shares کی بنیاد ہے، چھ ماہ کے دوران جو 31 دسمبر 2024 کو ختم ہوئے، فی خصص آمدنی 2.66 روپے رہی جب کہ پچیلے سال کے اس عرصے میں یہ 2.42 رویے تھی۔

مستقبل كانقطه نظر

جائزہ لینے والے دوسرے سہ ماہی کے دوران، اسٹیٹ بینک آف ہاکتان نے مانیزی ہالیسی کی شرح کو 450 بیسس پوائنش کم کر دیا۔ یہ ایک خوش آئند قدم ہے جو مستقبل میں ملک کی اقتصادی سر گرمیوں کو بہتر بنانے میں مددگار ثابت ہوگا۔ اس کی سے کمپنی کو اپنے مالیاتی اخراجات پر بڑھتے ہوئے دباؤ کو کم کرنے میں مجھی

بیلنس شیٹ کی تاریخ تک، ہارے پاس حکومت کے اداروں سے تقریباً 2.3 ارب رویے کی واجب الادا وصولیاں ہیں۔ ان وصولیوں کی اکثریت مرشتہ ایک سال سے واجب الادا ہے اور یہ سیلائیز مخلف حکومتی اداروں کو میندرز کے تحت اچھی نیت کے ساتھ فراہم کی گئی تھیں۔ ان واجبات کی وصولی میں اس قدر تاخیر کی مثال پہلے تھی نہیں ملتی، اور اس کا براہ راست اثر صنعت کی کار کردگی پر پڑ رہا ہے۔ اس کا اثر یہ بھی پڑ سکتا ہے کہ صنعت ان اداروں کو مزید سیلائیز فراہم نہ کریائے۔

اظهار تشكر

ہم اپنے ملازمین کی کوششوں اور محنت کو تسلیم کرنا چاہتے ہیں جو انہوں نے کمپنی کے مقاصد کے حصول کے لیے کی ہیں۔ مزید برآل، ہم اپنے اصولی افراد، کاروباری شراکت داروں اور معزز گاہوں کا بھی شکریہ ادا کرتے ہیں جو سمپنی میں اپنی مسلسل حمایت اور اعتاد فراہم کرتے ہیں۔

بورڈ آف ڈائریکٹرز کی جانب سے

مسز اختر خالد وحيد چيئر پر سن

جناب عثان خالد وحيد چف ایگزیگو آفیسر

28 فروری 2025

31 دسمبر 2024 کو اختتام پذیر ہونے والے چھ ماہ کی مجموعی (کنڈینسڈ) عبوری مالیاتی معلومات کے بارے میں ڈائر پکٹرز کا جائزہ

ہمیں یہ بتاتے ہوئے خوشی محسوس ہو رہی ہے کہ ہم نے کمپنی کی غیر آؤٹ شدہ انفرادی اور اجہامی مخضر عبوری مالی معلومات کا جائزہ تیار کیا ہے، جو 31 دسمبر 2024کو افتقام پذیر سہ مائی کے لیے ہے۔ اس رپورٹ میں ان اعداد و شار اور مالیاتی بوزیشن کا احاطہ کیا گیا ہے جو اس مدت کے دوران کمپنی کی کارکردگی کو ظاہر کرتی ہے۔ اس مشتر کہ مختصر عبوری مالی معلومات میں نہ صرف شکینی بلکہ شکینی کی زبلی کپنیوں کی مالی کارکردگی بھی شامل ہے، جن میں ہاری 98 فیصد ملکیتی وینچیر فارمییا اور مکمل ملکیت والی زبلی شکینی کی ایف بائیوسائنسز

کمپنی کے انفرادی اور مجموعی مالیاتی نتائج کی جھلکاں:

اس مت کے مالیاتی نتائج کا خلاصہ ذیل میں دیا گیا ہے:

		اجتماعي		انفرادي				
3 مہینے	3 مہينے	6 مهيني	6 مہینے	3 مهينے	3 مهيني	6 مهيني	6 مهينے	
31 - دَبر - 2023	31_د کمبر _ 2024	31_د کمبر_ 2023	31_د كبر_ 2024	31 - دئمبر - 2023	31_دىمبر_ 2024	31_دسمبر_ 2023	31_دسمبر_2024	

رویے ہزار میں

3,870,277	4,730,951	8,298,818	9,259,937	3,087,911	3,676,106	6,710,878	7,032,685	آمدنی۔خالص
1,474,929	2,089,716	3,194,276	3,942,718	1,152,836	1,459,865	2,490,130	2,766,703	مجموعي منافع
138,444	327,377	604,658	687,799	74,343	215,098	377,971	413,590	قبل از ٹیکس منافع
111,630	177,551	393,099	418,571	76,538	111,815	257,054	252,326	فيكسيشن
2.34	3.46	8.40	8.53	1.76	2.57	5.91	5.80	بعداز فيكس منافع

فيروزسنز ليبار ريز لميثة كا مالياتي اور آريشل جائزه:

کمپنی کی مشترکہ غالص فروخت 9,260 ملین روپے رہی، جو کہ پچھلے سال کی اس مدت کے مقابلے میں 12% اضافہ ظاہر کرتی ہے۔ کیلے کمپنی کی خالص فروخت 7,033 ملین روپ رہی، جو کہ چھلے سال کی ای مدت کے مقابلے میں %5 اضافہ کو ظاہر کرتی ہے۔

مار کیٹ میں دستیاب جزک مصنوعات کی فروخت میں %25 اضافہ ہوا ہے، جبکہ ادارہ جاتی سطح پر جزک اور طبی آلات کی فروخت میں %24 کی دیکھنے میں آئی ہے۔ ادارہ جاتی فروخت میں کمی کی بنیادی وجہ وہ ملتی آلات ہیں جو مجھلے سال کی ای مدت میں میندار کے ذریعے فراہم کیے گئے تھے

کمپنی کا مجموعی منافع (بی بی) مارجن اس وقت 39% ہے، جبکہ کچھلے سال کی ای مدت میں یہ 37% تھا۔ بی بی مارجن میں یہ اضافہ بنیادی طور پر فروخت کے مرکب میں تبریلی اور قیمتوں میں اضافے کی عکاس کرتا ہے۔

فروخت اور تقتیم کے اخراجات میں 7% اضافہ ہوا ہے ، جبکہ دیگر اخراجات میں پچیلے سال کی ای مدت کے مقابلے میں 18% اضافہ ہوا ہے۔

آپریشنز سے حاصل ہونے والا منافع %23 برها، لیکن ممیل کے بعد منافع میں %2 کی آئی۔بعد از ممیل منافع میں کی بنیادی طور پر مالی اخراجات اور ممیل کے اخراجات میں اضافے کی وجہ سے ہوئی ہے۔

ملی اخراجات میں %53 کا اضافہ اس بات کی نشاندہی کرتا ہے کہ کمپنی کو زیادہ قرضوں پر سود ادا کرنا پڑا ہے، جو کہ اس وجہ سے ہوا کہ حکومتی اداروں کی طرف سے ادائیگیاں تاخیر سے ہو رہی ہیں۔ اس کے نتیج میں ممپنی کو کیش فلو کے فرق کو پورا کرنے کے لیے Running Finance کا استعال کرنا پڑا۔ یہ تجارتی قرضے زیادہ تر ان رقبول پر مشتل ہیں جو سمین کو حکومتی اداروں سے میدیکل ڈیوائسز کی سپائی کے بدلے وصول کرنی ہیں۔ سمین ان اداروں سے جلدی ادائیگی حاصل کرتے کے لیے مسلس رابطے میں ہے تاکہ مالی دباؤ کو کم کیا جا سکے اور کاروبار کی مالی صور تحال کو بہتر بنایا جا سکے۔

مؤثر کمیں کی شرح %39 پر بند ہوئی ہے، جب کہ پچھلے سال کے اس عرصے میں یہ %32 تھی۔ اس اضافے کی بنیادی وجہ وفاقی تحومت کی جانب سے برآمدی فروخت پر کمیس کے نظام میں تبدیلی ہے۔

چہ ماہ کے لئے 31 وسمبر 2024 کو ختم ہونے والی کمائی فی شیئر (EPS) 5.80 رویے پر بند ہوئی جو پچھلے سال کے اس عرصے میں 5.91 رویے تھی۔





OUR FINANCIAL STATEMENTS

INDEPENDENT	AUDITOR'S RE	VIEW REPORT



KPMG Taseer Hadi & Co. Chartered Accountants 351 Shadman-1, Jail Road, Lahore 54000 Pakistan +92 (42) 111-KPMGTH (576484), Fax +92 (42) 3742 9907

INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Ferozsons Laboratories Limited

Report on the Review of Condensed Interim Unconsolidated Financial Statements

Introduction

We have reviewed the accompanying condensed interim unconsolidated statement of financial position of Ferozsons Laboratories Limited ("the company") as at 31 December 2024 and the related condensed interim unconsolidated statement of profit or loss, condensed interim unconsolidated statement of comprehensive income, condensed interim unconsolidated statement of changes in equity, condensed interim unconsolidated statement of cash flows and notes to the condensed interim unconsolidated financial statements for the six-month period then ended (here-in-after referred to as " condensed interim unconsolidated financial statements"). Management is responsible for the preparation and fair presentation of these condensed interim financial information in accordance with accounting and reporting standards as applicable in Pakistan for interim financial reporting. Our responsibility is to express a conclusion on these condensed interim financial statements based on our review.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed interim unconsolidated financial statements are not prepared, in all material respects, in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting.

Other matters

The figures for the quarter ended 31 December 2024, and 31 December 2023, in condensed interim unconsolidated statement of profit or loss and condensed interim unconsolidated statement of comprehensive income have not been reviewed by us and we do not express a conclusion on them.

The engagement partner for the review resulting in this independent auditor's report is Ahsin Tariq.

Lahore

Date: 28 February 2025

UDIN: RR202410119xZjeJ0dYG

KPMG Taseer Hadi & Co. Chartered Accountants

April Jases Hadi & Co.

RR0825

18,195,076,210 15,015,929,825

Ferozsons Laboratories Limited

Condensed Interim Unconsolidated Statement of Financial Position

As at 31 December 2024

	Un-audited	Audited			Un-audited	∢
	31 December	30 June			31 December	cc
	2024	2024			2024	
EQUITY AND LIABILITIES Note	Rupees		ASSETS	Note	Rupees	

ASSELS	Non current assets	1,500,000,000 T.500,000,000 Long term investments - related parties Long term deposits Long term deposits	434.690.520 434.690.520
Note		1,500,	3 434.
EQUILY AND LIABILITIES	Share capital and reserves.	Authorized share capital 150,000,000 (2024: 150,000,000) ordinary shares of Rs. 10 each	Issued, subscribed and paid up capital

321,843

321,843 3,129,660,820 5,524,719,101 9,089,392,284

40,485,226 401,063,555 9,777,325 7,083,328,727

6,562,853,847 32,010,638 414,472,147 9,922,000 7,019,258,632

6,632,002,621

 ∞ 6

Audited 30 June

2024

Cash and Daily Dalances
Cash all Jally Jally Cash

Current assets

3,212,263,581 5,320,197,432

8,967,473,376

179,210,782 233,838,302 451,860,597

217,589,696 229,272,945 410,562,458 309,707,662

375,541,979 268,898,922

2,667,104,079 317,364,647 11,175,817,578

12 13

7,932,601,098

3,972,815,154 2,199,853,473 168,870,294

105,332,519 4,338,651,795 2,580,231,777

10 11

108,927,783 143,830,767 44,310,185

108,927,783	143,830,767	44,310,185	1,116,002,712	1,413,071,447
130,155,230	191,850,356	41,513,207	1,042,410,077	1,405,928,870

15,465,090	70 24,886,380	12,761,867	70 1,599,172,831	306,617,234	2,407,658,889	91 96,507,363	172,315,348	200 300 300 1
18,743,104	43,954,070	13,797,748	2,681,934,870	217,344,418	4,518,863,364	100,719,891	104,397,591	720 224 007 4
								l

- Long term musharaka - secured

- Long term loans - secured

Current liabilities Current portion of: Short term borrowings - secured

Unclaimed dividend

Accrued mark-up

Trade and other payables

Contract liabilities

- Deferred grant

4,635,385,002		15,015,929,825	
050,557,860,7		18,195,076,210	
	7		

Contingencies and commitments

statements.
financial
nsolidated
im unco
sed inter
e conder
of thes
part
n integral
form a
1 to 21
s from
ed note
annex
The

Non current liabilities

Long term musharaka - secured

Deferred taxation

Deferred grant

Long term loans - secured

Revaluation surplus on property,

Capital reserve

plant and equipment

Accumulated profit

Ferozsons Laboratories Limited

Condensed Interim Unconsolidated Statement of Profit or Loss (Un-audited)

For the half year and quarter ended 31 December 2024

		Half year	ended -	Quarter	ended
		31 December	31 December	31 December	31 December
		2024	2023	2024	2023
			Restated		Restated
	Note		Rupe	ees	
Revenue - net	14	7,032,685,165	6,710,877,978	3,676,106,265	3,087,910,727
Cost of sales	15	(4,265,982,079)	(4,220,747,657)	(2,216,241,677)	(1,935,074,651)
Gross profit		2,766,703,086	2,490,130,321	1,459,864,588	1,152,836,076
Administrative expenses		(423,921,230)	(359,531,783)	(218,157,111)	(168,404,942)
Selling and distribution expenses		(1,664,524,241)	(1,551,919,488)	(924,365,157)	(770,773,965)
Other expenses		(64,537,566)	(136,561,384)	(45,048,077)	(110,764,104)
Other income		75,653,704	116,610,353	59,960,413	72,539,859
Profit from operations		689,373,753	558,728,019	332,254,656	175,432,924
Finance cost		(275,783,784)	(180,756,913)	(117,157,036)	(101,089,654)
Profit before income tax, final tax	and				
minimum tax		413,589,969	377,971,106	215,097,620	74,343,270
Minimum tax differential		(13,431,470)	-	(9,451,049)	-
Final tax		-	(5,685,667)	4,801,194	(27,569)
Profit before income tax		400,158,499	372,285,439	210,447,765	74,315,701
Income tax		(147,832,435)	(115,231,896)	(98,632,608)	2,221,878
Profit after taxation		252,326,064	257,053,543	111,815,157	76,537,579
Earnings per share - basic and diluted	1	5.80	5.91	2.57	1.76

Chief Executive Officer	Chief Financial Officer	Director
the annexed notes from 1 to 21 form an integral part of these c	ondensed intermi unconsolidated imanciai statements	•
The annexed notes from 1 to 21 form an integral part of these c	ondensed interim unconsolidated financial statements	

Ferozsons Laboratories Limited

Condensed Interim Unconsolidated Statement of Comprehensive Income (Un-audited)

For the half year and quarter ended 31 December 2024

	Half year ended		Quarte	ended
	31 December	31 December	31 December	31 December
	2024	2023	2024	2023
		Ruj	pees	
Profit after taxation	252,326,064	257,053,543	111,815,157	76,537,579
Items that will not be subsequently reclassified to profit or loss				
Other comprehensive income for the period	-	-	-	-
Total comprehensive income for the period	252,326,064	257,053,543	111,815,157	76,537,579

Items that will not be subsequently reclassified to profit or loss				
Other comprehensive income for the period	-	-	-	-
Total comprehensive income for the period	252,326,064	257,053,543	111,815,157	76,537,579
		Carrier	1.6	
The annexed notes from 1 to 21 form an integral pa	rt of these condensed	interim unconsolid	ated financial staten	ients.

Ferozsons Laboratories Limited

Condensed Interim Unconsolidated Statement of Changes in Equity (Un-audited) For the half year ended 31 December 2024

		Capital	Capital Reserve	Revenue Reserve	
	Share capital	Capital reserve	Revaluation surplus on property, plant and equipment	Accumulated	Total
			Rupees		
Balance as at 01 July 2023	434,690,520	321,843	968,377,365	4,881,302,916	6,284,692,644
Total comprehensive income for the period	ı	1	1	257,053,543	257,053,543
Surplus transferred to accumulated profit					
- on account of incremental depreciation charged during the period - net of tax	ı	1	(18,045,873)	18,045,873	1
Balance as at 31 December 2023 - unaudited	434,690,520	321,843	950,331,492	5,156,402,332	6,541,746,187
Balance as at 01 July 2024	434,690,520	321,843	3,212,263,581	5,320,197,432	8,967,473,376
Total comprehensive income for the period	ı	1	ı	252,326,064	252,326,064
Surplus transferred to accumulated profit					
- on account of incremental depreciation charged during the period - net of tax	ı	1	(82,602,761)	82,602,761	
Transactions with owners of the Company, recognized directly in Equity - Distributions					
- final dividend for the year ended 30 June 2024 at Rs. 3 per share	ı	1	1	(130,407,156)	(130,407,156)
Balance as at 31 December 2024 - unaudited	434,690,520	321,843	3,129,660,820	5,524,719,101	9,089,392,284

The annexed notes from 1 to 21 form an integral part of these condensed interim unconsolidated financial statements.

Condensed Interim Financial Information For The Half Year Ended 31 December 2024

Director

Ferozsons Laboratories Limited

Condensed Interim Unconsolidated Statement of Cash Flows (Un-audited) For the half year ended 31 December 2024

For the half year ended 31 December 2024		
	Half year	
	31 December 2024	31 December 2023
	2021	Restated
Cash flow from operating activities	Rupe	es
Profit after taxation	252,326,064	257,053,543
Adjustments for non - cash and other items	, , , , , , ,	, , .
Depreciation on property, plant and equipment	306,252,658	203,598,060
Amortisation of intangible assets	8,474,588	10,248,436
Provision of loss allowance	21,061,750	96,268,345
Gain on disposal of property, plant and equipment Finance costs	(6,417,824) 275,783,784	(16,005,326) 180,756,913
Gain on re-measurement of short term investments to fair value	(41,545,148)	(34,667,803)
Dividend income	(28,565)	(1,760,021)
Profit on bank deposits	(2,353,106)	(1,819,345)
Share in profit of Farmacia	(13,408,592)	(9,633,314)
Workers' Profit Participation Fund	22,354,596	25,469,358
Central Research Fund Workers' Welfare Fund	4,516,080 11,147,355	5,145,325 9,678,356
Minimum tax	13,431,470	7,076,330
Final tax	-	5,685,667
Income tax	147,832,435	115,231,896
	747,101,481	588,196,547
Cash generated from operations before working capital changes	999,427,545	845,250,090
Effect on cash flow due to working capital changes		
(Increase) / decrease in current assets	(22 (20 024)	(16,509,303)
Stores, spare parts and loose tools Stock in trade	(23,620,924) (365,836,641)	(221,128,611)
Trade debts - considered good	(399,628,819)	(1,206,618,097)
Loans and advances - considered good	(140,837,368)	(302,681,272)
Deposits and prepayments	(40,190,149)	(25,079,147)
Other receivables	4,565,357	(5,184,736)
(Decrease) / Increase in current liabilities	(965,548,544)	(1,777,201,166)
Trade and other payables Contract liability	1,086,621,669	29,338,344 29,575,977
Contract hability	(89,272,816)	58,914,321
Cash generated from / (used in) operations	1,031,227,854	(873,036,755)
Income tax paid	(180,126,931)	(154,381,273)
Minimum tax paid Final tax paid	(13,431,470)	(3,410,284)
Workers' Profit Participation Fund paid	(35,251,527)	(4,097,000)
Central Research Fund paid	(6,626,135)	(2,987,248)
Net cash generated from / (used in) operating activities	795,791,791	(1,037,912,560)
Cash flow from investing activities		
Fixed capital expenditure incurred	(238,505,800)	(170,940,153)
Intangibles acquired	-	(8,287,500)
Proceeds from sale of property, plant and equipment	7,819,740	19,401,906
Dividend income received	28,565	-
Profit on bank deposits received Short term investments - net	2,353,107 (2,250,016,952)	1,819,345
Long term deposits	(144,675)	-
Net cash used in investing activities	(2,478,466,015)	(158,006,402)
Cash flow from financing activities	()	(, , - ,
Long term loan repaid	(9,629,636)	(20,343,525)
Long term loan received	32,374,000	(20,343,323)
Long term musharaka received	90,002,620	91,192,200
Long term musharaka paid	(22,915,341)	-
Finance cost paid	(343,701,541)	(132,661,492)
Dividend paid	(126,194,628)	(265,619)
Net cash used in financing activities	(380,064,526)	(62,078,436)
Net decrease in cash and cash equivalents Cash and cash equivalents at the beginning of the period	(2,062,738,750) (2,138,759,967)	(1,257,997,398) (517,542,117)
Cash and cash equivalents at the original of the period	(4,201,498,717)	(1,775,539,515)
Cash and cash equivalents comprise of the following		
	217 264 647	242 252 007
Cash and bank balances Short term borrowings - secured	317,364,647 (4,518,863,364)	243,253,007 (2,018,792,522)
Short with contourings secured	(4,201,498,717)	(1,775,539,515)
The annexed notes from 1 to 21 form an integral part of these condensed interim unconsolidated financial statements.		

Chief Executive Officer Chief Financial Officer Director

Ferozsons Laboratories Limited

Notes to the Condensed Interim Unconsolidated Financial Statements (Un-audited)

For the half year ended 31 December 2024

1 Reporting entity

Ferozsons Laboratories Limited ("the Company") was incorporated as a private limited company on 28 January 1954 and was converted into a public limited company on 08 September 1960. The Company is listed on Pakistan Stock Exchange and is primarily engaged in the imports, manufacture and sale of pharmaceutical products and medical devices. Its registered office is situated at 197-A, The Mall, Rawalpindi and the manufacturing facility is located at Amangarh, Nowshera, Khyber Pakhtunkhwa.

2 **Basis of preparation**

Separate financial statements 2.1

These condensed interim unconsolidated financial statements are the separate financial statements of the Company in which investments in subsidiaries and associates are accounted for on the basis of direct equity interest rather than on the basis of reported results and net assets of the investees. Consolidated condensed interim financial statements of the Company are prepared and presented separately.

The Company has following major investments:

Name of the company / firm

Shareholding

- BF Biosciences Limited (Subsidiary)

57.36% 98%

- Farmacia (Partnership)

Ferozsons Laboratories Limited (FLL) holds a significant investment in its subsidiary, BF Biosciences Limited (BF). On October 21, 2024, BF Biosciences was listed on the Pakistan Stock Exchange (PSX) through an Initial Public Offering (IPO). Prior to the IPO, FLL held 80% of the shareholding in BF. As part of the IPO, BF Biosciences issued 25 million shares with a face value of Rs. 3 per share at a strike price of Rs. 77 per share. The total funds raised through the IPO amounted to Rs. 1,925 million, which are primarily intended for the purchase of plant and machinery, acquiring export certifications and to finance working capital requirements.

Following the IPO, Ferozsons Laboratories Limited's shareholding in BF Biosciences was reduced from 80% to 57.36%

2.2 Statement of compliance

These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting. The accounting and reporting standards as applicable in Pakistan for interim financial reporting comprise of:

International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017;

- Islamic Financial Accounting Standards (IFAS) issued by the Institute of Chartered Accountants of Pakistan as notified under the Companies Act, 2017; and
- Provisions of and directives issued under the Companies Act, 2017.

Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

2.3 **Basis of accounting**

- 2.3.1 These condensed interim unconsolidated financial statements comprises the condensed interim unconsolidated statement of financial position of the Company as at 31 December 2024 and the related condensed interim unconsolidated statement of profit or loss, condensed interim unconsolidated statement of comprehensive income, condensed interim unconsolidated statement of changes in equity and condensed interim unconsolidated statement of cash flows together with the notes forming part thereof.
- 2.3.2 These condensed interim unconsolidated financial statements does not include all of the information required for full annual financial statements and should be read in conjunction with the annual unconsolidated financial statements for the year ended 30 June 2024. Selected explanatory notes are included to explain events and transactions that are significant to and understanding of the changes in the Company's financial position and performance since the last annual financial statements.
- 2.3.3 Comparative unconsolidated statement of financial position's numbers are extracted from the annual audited unconsolidated financial statements of the Company for the year ended 30 June 2024, whereas comparative unconsolidated statement of profit or loss, statement of comprehensive income, statement of changes in equity and cash flow statement are stated from unaudited condensed interim unconsolidated financial statements of the Company for the period ended 31 December 2023.
- 2.3.4 These condensed interim unconsolidated financial statements are unaudited and being submitted to the shareholders as required under Section 237 of the Companies Act, 2017 and the Listing Regulations of the Pakistan Stock Exchange Limited.

2.4 Judgements and estimates

In preparing these condensed interim unconsolidated financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgments made by the management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the unconsolidated financial statements as at and for the year ended 30 June 2024.

2.5 Statement of consistency in accounting policies

2.5.1 The accounting policies and the methods of computation adopted in the preparation of these condensed interim unconsolidated financial statements are same as those applied in the preparation of the annual audited financial statements for the year ended 30 June 2024.

2.5.2 Changes in accounting standards, interpretations and pronouncements

The following amendments to published standards are mandatory for the financial year beginning on 1 January 2024 and are relevant to the Company:

Classification of liabilities as current or non-current -Amendments to IAS 1

Non-current Liabilities with Covenants with Amendment to IAS 1

Lease Liability in a Sale and Leaseback Amendment to IFRS 16

Supplier Finance Arrangements Amendments to IAS 7 and IFRS 7

Standards, amendments and interpretations to accounting and reporting standards that are not yet effective

The following International Financial Reporting Standards (IFRS Standards) as notified under the Companies Act, 2017 and the amendments and interpretations thereto will be effective for accounting periods beginning on or after 1 January 2025:

Lack of Exchangeability -Amendments to IAS 21

2.5.3 Restatement in Financial Statements - Change in Accounting policy

2.5.3.1 Classification of taxes and levies

The Institute of Chartered Accountants of Pakistan (ICAP) vide circular 07/2024 dated 15 May 2024 issued the application guidance on accounting for minimum taxes and final taxes. As per the guidance, minimum tax and final tax should be classified as 'levies' and not income tax in the unconsolidated statement of profit or loss.

Since, the impact of the said changes is material, per the abovesaid guide and IAS 8 'Accounting policies, changes in accounting estimates and others', the changes are to be applied retrospectively.

Accordingly, the Company has restated its comparative information by reclassifying levies amounting to Rs. nil and Rs. 5.69 million from Income tax to minimum tax and Final tax respectively, in the unconsolidated statement of profit or loss.

In the unconsolidated statement of cashflows, the Income tax paid under the operating activities has been reclassified by Rs. nil million and Rs. 3.4 million to minimum tax paid and final tax paid.

	For the pe	eriod ended 31 Decem	December 2023			
	As previously reported	Adjustments 'Increase / (Decrease)	As restated			
Statement of profit or loss		Rupees				
Profit before income tax, final tax						
and minimum tax	377,971,106	-	377,971,106			
Minimum tax differential	-	-	-			
Final tax	-	(5,685,667)	(5,685,667)			
Profit before income tax	377,971,106	(5,685,667)	372,285,439			
Income tax	(120,917,563)	(5,685,667)	(115,231,896)			
Profit after taxation	257,053,543	(11,371,334)	257,053,543			

	For the period ended 31 December 2023				
Statement of Cash Flows	As previously reported	Adjustments 'Increase / (Decrease)Rupees	As restated		
Cash flow from Operating Activities		-			
Income tax paid	(157,791,557)	3,410,284	(154,381,273)		
Minimum tax paid	- 1	-	-		
Final tax paid	-	(3,410,284)	(3,410,284)		
Other cashflows from operating activities	(880,121,003)	-	(880,121,003)		
Net cash used in operating activities	(1,037,912,560)	-	(1,037,912,560)		
Cash flow from investing activities					
Net cash generated from investing activities	(158,006,402)	-	(158,006,402)		
Cash flow from financing activities					
Net cash used in financing activities	(62,078,436)	-	(62,078,436)		
Net decrease in cash and cash equivalents	(1,257,997,398)		(1,257,997,398)		

- 2.5.3.2 The impact of aforementioned restatement is not material on unconsolidated statement of financial position as at 01 July 2024 and condensed interim unconsolidated financial position as at 31 December 2024.
- 2.5.3.3 Profit before taxation has been restated in line with above explained change, however there is no impact on the investing and financing cashflows for the period ended 31 December 2023.
- 2.5.3.4 There is no impact on earning per share that needs to be disclosed in the condensed interim unconsolidated financial statements.

Issued, subscribed and paid-up capital 3

issued, subscribed und puid up cupitui				
	Un-audite d	Audited	Un-audited	Audited
	31 December	30 June	31 December	30 June
	2024	2024	2024	2024
	(Number	of shares)	(Rupe	es)
<u>Issued, subscribed and paid-</u> <u>up share capital</u>				
Voting ordinary shares of Rs. 10 each				
fully paid up in cash	1,441,952	1,441,952	14,419,520	14,419,520
Voting ordinary shares of Rs. 10 each issued in lieu of NWF Industries Limited and Sargodha Oil and Flour Mills Limited since merged	119,600	119,600	1,196,000	1,196,000
Voting ordinary shares of Rs. 10 each				
issued as bonus shares	41,907,500	41,907,500	419,075,000	419,075,000
	43,469,052	43,469,052	434,690,520	434,690,520

KFW Factors (Private) Limited, an associated company holds 11,933,194 (30 June 2024: 11,933,194) ordinary shares of Rs. 10 each of the Company, representing 27.45% (30 June 2024: 27.45%) of the equity held.

			Un-audited	Audited
			31 December	30 June
			2024	2024
4	Long term loan - secured	Note	Rupees	S
	Allied Bank Limited - SBP LTFF Renewable Energy Faysal Bank Limited - SBP Islamic Renewable	4.1	96,296,289	105,925,925
	Energy Finance Scheme	4.2	107,913,000	75,539,000
			204,209,289	181,464,925
	Less:			
	Unamortized Deferred Grant		(55,310,955)	(57,072,052)
			148,898,334	124,392,873
	Current portion of long term loans		(18,743,104)	(15,465,090)
			130,155,230	108,927,783

- 4.1 This represents term finance facility obtained under "SBP Finance Scheme for Renewable Energy" introduced by Government of Pakistan in order to finance the installation / commissioning of solar power system. This loan carries the fixed markup rate of 6% (SBP rate of 2% + bank's spread of 4% per annum). The principal amount is payable in twenty-seven equal quarterly installments. During the period, the Company has made repayments amounting to Rs. 9.63 million.
- 4.2 This represents term finance facility obtained under "SBP Islamic Renewable Energy Finance Scheme" introduced by Government of Pakistan in order to Finance installation of Solar Power Plant of 1MW. This loan carries the SBP's IFRE rate of 2% + bank's spread of 4.00% per annum.

			Un-audited	Audited
			31 December	30 June
			2024	2024
5	Long term musharaka - secured	Note	Rupees	S
	Islamic mode of financing			
	First Habib Modaraba - Financial Institution	5.1	235,804,426	168,717,147
	Total		235,804,426	168,717,147
	Current portion of musharaka		(43,954,070)	(24,886,380)
	Non current portion		191,850,356	143,830,767

5.1 This represents financing facility obtained under "Diminishing Musharaka" from First Habib Modaraba for the purpose of purchase of vehicles. During the period, the Company has made repayments amounting to Rs. 22.92 million which includes down payment amounting to Rs. 9 million.

Short term borrowings - secured

All terms and conditions applicable to short-term borrowings remain the same as those disclosed in the annual audited unconsolidated financial statements of the Company for the year ended June 30, 2024, except for the new short-term loans obtained during the period under Shariah-compliant arrangements and mark-up arrangements, amounting to Rs. 3,000 million and Rs. 1,229 million, respectively. These short-term loans carry a profit/mark-up ranging from KIBOR minus 3% to KIBOR minus 2.75%.

7 **Contingencies and commitments**

7.1 **Contingencies**

There is no significant change in the status of the contingencies as reported in the preceding published annual financial statements of the Company for the year ended 30 June 2024.

7.2 **Commitments**

7.2 Letter of credits

7.2.1 Under Mark up arrangements

Out of the aggregate facility of Rs. 3,550 million (30 June 2024: Rs. 3,400 million) for opening letters of credit, the amount utilized as at 31 December 2024 for capital expenditure was Rs. Nil (30 June 2024: Nil) and for other than capital expenditure was Rs. 369.49 million (30 June 2024: Rs. 282.84 million). These facilities are secured by either joint pari passu charge over present and future current assets of the Company with 25% margin over plant and machinery, joint pari passu charge over present and future current assets of the Company with 25% margin, lien on investments of the Company placed with HBL mutual funds or lien over the import documents (30 June 2024: either joint pari passu charge over present and future current assets of the Company with 25% margin over plant and machinery, joint pari passu charge over present and future current assets of the Company with 25% margin, lien on investments of the Company placed with HBL mutual funds or lien over the import documents).

7.2.2 Under Shariah compliant arrangements

The Company have facilities i.e. letters of credit of Rs. 2,500 million (30 June 2024: Rs. 1,850 million) available from Islamic banks. The amount utilized as at 31 December 2024 for capital expenditure was Rs. Nil (30 June 2024: Rs. Nil) and for other than capital expenditure was Rs. 98.49 million (30 June 2024: Rs. 157.45 million). These facilities are secured by either joint pari passu charge over all present and future current assets and plant and machinery of the Company with 25% margin, joint pari passu charge over all present and future current asset of the Company with 25% margin, or lien over import documents (30 June 2024: either joint pari passu charge over all present and future current assets and plant and machinery of the Company with 25% margin, joint pari passu charge over all present and future current asset of the Company with 25% margin, or lien over import documents).

7.2.2 Guarantees issued by banks on behalf of the Company

7.2.2.1 Under Mark up arrangements

Out of the aggregate facility of Rs. 1,200 million (30 June 2024: Rs. 1,200 million) for letter of guarantees (which is the sublimit of running finance and letter of credits), the amount utilized as at 31 December 2024 was Rs. 325.21 million (30 June 2024: Rs. 380.57 million).

7.2.2.2 Under Shariah compliant arrangements

The Company has facility i.e. letter of guarantee of Rs. 275 million (30 June 2024: Rs. 175 million) available from Islamic bank, the amount utilized at 31 December 2024 was Rs. 4.49 million (30 June 2024: Rs. 14.57 million).

7.2.2.3 Guarantees issued by the Company on behalf of the Subsidiary

The Company has approved cross corporate guarantees in favor of lenders / financial institutions of the subsidiary company up to Rs. 3,500 million (30 June 2024: Rs. 3,500 million) for a tenor of 10 years. Out of this approved limit, corporate guarantees amounting to Rs. 3,500 million (30 June 2024: Rs. 3,500 million) for a tenor of 10 years have been provided to banks / financial institutions till date.

				Un-audited	Audited
				31 December	30 June
				2024	2024
8	Prope	Cost Opening balance at beginning of the per Additions / transfers during the period / Revaluation surplus - net Disposals / write offs during the period / Closing balance at end of the period / ye Less: Accumulated depreciation Opening balance at beginning of the per Depreciation for the period / year On disposals Elimination of accumulated depreciation Closing balance at end of the period / year	Note	Rupe	es
	Opera	ating fixed assets	8.1	6,340,625,664	6,439,453,250
	Capita	al work-in-progress		222,228,183	192,549,371
				6,562,853,847	6,632,002,621
	8.1	Operating fixed assets			
		<u>Cost</u>			
		Opening balance at beginning of the period	od / year	7,036,058,135	4,452,061,683
		Additions / transfers during the period / y	ear	208,826,988	474,888,719
		*		-	2,238,924,837
		Disposals / write offs during the period / y	/ear	(18,033,435)	(129,817,104)
		Closing balance at end of the period / year	r	7,226,851,688	7,036,058,135
		Less: Accumulated depreciation			
		Opening balance at beginning of the period	od / year	596,604,885	1,218,536,502
		Depreciation for the period / year		306,252,658	423,367,440
		On disposals		(16,631,519)	(78,443,926)
		Elimination of accumulated depreciation	on revaluation	-	(966,855,131)
		Closing balance at end of the period / year	r	886,226,024	596,604,885
		Operating fixed assets - net book value		6,340,625,664	6,439,453,250
9	Long	term investments - related parties			
	Relate	ed parties - at cost			
	Farma	acia (Partnership firm)	9.1	262,472,187	249,063,595
	BF Bi	iosciences Limited	9.2	151,999,960	151,999,960
				414,472,147	401,063,555

- 9.1 This represents the Company's 98% share in "Farmacia", a subsidiary partnership duly registered under the Partnership Act, 1932 and engaged in operating retail pharmacy.
- BF Biosciences Limited has been set up for establishing a Biotech Pharmaceutical Plant to manufacture 9.2 mainly Cancer and Hepatitis related medicines. The Company was formed pursuant to signing of an agreement between M/s Ferozsons Laboratories Limited and M/s Grupo Empresarial Bagó S.A. The company holds 57.36% (30 June 2024: 80%) of equity of the subsidiary.

10 Stock in trade

10.1 This includes amount charged to unconsolidated condensed interim statement of profit or loss on account of write down of raw material and work in progress to net realizable value amounts to Rs. 34.48 million (30 June 2024: Rs. 47.80 million) and finished goods to net realizable value amounts to Rs. 88.63 million (30 June 2024: 114.19 million).

11 Trade debts - considered good

11.1 This includes provision outstanding on account of impairment loss allowance amounting to Rs. 239.69 million (30 June 2024: Rs. 220.44 million).

			Un-audited	Audited
			31 December	30 June
			2024	2024
S	hort term investments	Note	Rupe	es
<u>I</u>	nvestments at fair value through profit or loss			
N	Iutual fund	12.1	2,667,104,079	375,541,979
1	2.1 These investments are measured at 'fair value through Profit or Loss'			
	Fair value at 01 July		375,541,979	362,396,582
	Acquistion/(Redemption) during the year-net		2,249,988,387	(60,118,104)
	Dividend re-invested during the period / year		28,565	28,233,952
	Realized gain on sale of investments during the period / year		-	6,027,500
	Unrealized gain on re-measurement of investment during the period / year		41,545,148	39,002,049
	Fair value at 31 December / 30 June	12.1.1	2,667,104,079	375,541,979
1	2.1.1 Mutual fund wise detail is as follows:			

	Units	;	Fair v	alue
	Un-audited	Audited	Un-audited	Audited
	31 December	30 June	31 December	30 June
	2024	2024	2024	2024
	Numb	er	Rupe	ees
HBL Money Market Fund	3,364,423	3,364,423	377,920,299	348,190,571
MCB Cash Management				
Optimizer Fund	4,520,306	10,939	503,203,337	1,114,288
HBL Cash Fund	15,909,222	249,626	1,785,490,462	25,764,090
Pakistan Cash Management Fund	12,673	9,387	489,981	473,030
			2,667,104,079	375,541,979

The investments amounting to Rs. 333.33 million (30 June 2024: Rs. 333.33 million) are marked under lien against short term borrowing facilities availed by the Company. Further, the gain earned from these investments is under non shariah compliant arrangement.

Cash and bank balances

12

- 13.1 These include current account of Rs. 0.097 million (30 June 2024: Rs. 24.48 million) maintained under Shariah compliant arrangements.
- 13.2 These include deposit accounts of Rs. 5.72 million (30 June 2024: Rs. 13.26 million) under mark up arrangements, which carry interest rates ranging from 10.00% - 20.50% (30 June 2024: 19.02% to 20.51%) per annum.
- These also include deposit account of Rs. 2.09 million (30 June 2024: Rs. 0.02 million) under Shariah compliant arrangements, which carries profit rates ranging from 5.87% - 11.01% (30 June 2024: 10.00% to 11.01%) per annum.

			(Un-audited) Ha	alf year ended
			31 December	31 December
			2024	2023
14 R	Revenue -	net	Rup	ees
(Gross sale	es:		
	Local		7,666,639,581	7,066,628,379
	Export		527,119,147	429,139,239
			8,193,758,728	7,495,767,618
I	Less:			
	Sales re	eturns	(62,432,969)	(25,269,377)
	Discour	nts	(1,040,980,957)	(706,700,470)
	Sales ta	X.	(57,659,637)	(52,919,793)
			(1,161,073,563)	(784,889,640)
			7,032,685,165	6,710,877,978
14	4.1 Dis	aggregation of Revenue (Net sales)		
	Pri	mary Geographical Markets		
	Pak	xistan	6,505,566,018	6,281,738,740
	Afg	ghanistan	229,188,977	157,764,768
	Sri	Lanka	125,185,244	159,748,547
	Phi	lippines	69,648,948	44,644,781
	My	anmar	44,695,948	14,698,310
	Kei	nya	21,501,314	29,135,294
	Kyı	rgyzstan	16,505,216	17,017,604
	Oth	ners	20,393,500	6,129,934
			7,032,685,165	6,710,877,978

				(Un-audited) Ha	alf year ended
				31 December	31 December
				2024	2023
			Note	Rup	ees
15	Cost	of sales			
	Raw a	and packing materials consumed	15.1	2,044,571,387	2,206,335,385
	Salari	es, wages and other benefits		302,907,360	284,750,635
	Fuel a	and power		97,461,470	82,793,370
	Repai	r and maintenance		20,485,381	15,549,898
	Stores	s, spare parts and loose tools consumed		89,230,970	60,292,412
	Freigl	nt and forwarding		26,174,591	33,224,082
	Packi	ng charges		54,825,142	9,517,718
	Rent,	rates and taxes		4,036,123	7,067,003
	Posta	ge and telephone		4,943,222	3,864,871
	Insura	nnce		15,003,535	15,231,863
	Trave	lling and conveyance		15,711,214	16,501,336
	Cante	en expenses		22,229,727	14,993,680
	Depre	eciation on property, plant and equipment		193,850,369	130,842,884
	Labor	ratory and other expenses		7,672,268	17,543,228
				2,899,102,759	2,898,508,365
	Work	in process:			
	Ope	ening		243,120,575	157,743,377
	Clos	sing		(146,737,096)	(285,143,011)
				96,383,479	(127,399,634)
	Cost	of goods manufactured		2,995,486,238	2,771,108,731
	Finish	ned stock:			
	Ope	ening		2,219,562,963	1,184,462,133
	_	chases made during the period		1,252,670,796	2,793,159,609
		sing - net of provision		(2,201,737,918)	(2,527,982,816)
				1,270,495,841	1,449,638,926
				4,265,982,079	4,220,747,657
	15.1	Raw and packing materials consumed	l		
		Opening		1,302,778,758	1,400,272,609
		Purchases made during the period		1,837,985,385	2,231,274,588
		i dichases made during the period		3,140,764,143	3,631,547,197
					,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
		Closing - net of provision		(1,096,192,756)	(1,425,211,812)
				2,044,571,387	2,206,335,385

Related party transactions

The Company in the normal course of business carries out transactions with various related parties which include subsidiaries, associated companies, entities over which directors are able to exercise influence, staff retirement fund, directors and key management personnel. Transactions with related parties during the period are as follows:

			(Un-audited) Half year ended	year ended
Name of parties	Relationship	Transactions	31 December 2024	31 December 2023
			Rs	
Farmacia	98% owned subsidiary partnership firm	Sale of medicines - net of returns and discounts Payment received against sale of medicine	160,820,393	123,235,936 123,235,936
		Rentals	3,417,744	3,107,040
		Share of profit reinvested	13,408,592	9,633,314
BF Biosciences Limited	80% owned subsidiary company	Sale of medicines	584,840,213	369,317,981
		Payment received against sale of medicine	584,840,213	369,317,981
		Furthers of medicines Payment made against purchase of medicine	6.570,613	
		Expenses incurred by the Company on behalf of BFBL - net	3,136,074	1
		Receipts received by BFBL on behalf of the Company - net	12,626,203	498,390
		Receipt from BFBL - net	15,762,277	1 0
		Expenses incurred by BFBIO on behalf of the Company - net Payments made to BFBIO - net		33,756,942
		Corporate guarantee income	3,510,000	3,510,000
		Payment received against corporate guarantee income	3,510,000	3,510,000
Kev Management Personnel	K ev management nersonnel	Remineration including benefits and percuisiles	44.133.538	27.263.565
0	,	Cash dividend paid	6,048	
		Advance given against salary	. 1	1,931,316
				0000
Employees Frovident Fund	Fost employment benefit fund	Contribution towards employees provident fund	43,077,884	55,785,890
KFW Factors (Private) Limited	Common directorship	Cash dividend paid	35,799,582	•
Osman Khalid Waheed	Chief Executive Officer	Remuneration including benefits and perquisites	33,824,349	26,293,552
		Cash dividend paid	10,208,241	,
		Advance given against salary	500,000	ı
		Meeting Fee	110,000	20,000
Directors other than CEO	Non-Executive Directors	Meeting Fee	750,000	160,000
		Reimbursement of expenses	87,000	1
		Rental expense paid for building in use	2,816,781	2,995,549
		Cash dividend paid	3,356,034	1
Khan and Piracha	Common directorship	Payment made against services received	390,000	
National Management Foundation (LUMS)	Common directorship	Event sponsorship	5,000,000	5,000,000
Lahore Biennale Foundation (LBF)	Common directorship	Donation	2,500,000	1
	-		`	

Reconciliation of movement of liabilities to cash flows arising from financing activities (Un-audited)

		31 Dec	31 December 2024 (Un-audited)	ıdited)			311	31 December 2023 (Un-audited)	audited)	
	Unclaimed dividend	Accrued mark-up	Long term loan	Diminishing Musharka	Total	Unclaimed dividend	Accrued mark-up	Long term loan	Diminishing Musharka	Total
			:		¥	- Rupees				
Balance as at 01 July	96,507,363	172,315,348	181,464,925	168,717,147	619,004,783	97,332,707	42,140,456	128,925,926		268,399,089
Changes from financing cash flows										
Dividend paid	(126,194,628)				(126,194,628)	(265,619)		•		(265,619)
Proceeds from long term loan			32,374,000		32,374,000			•	•	,
Repayment of long term loan		•	(9,629,636)		(9,629,636)			(20,343,525)	•	(20,343,525)
Finance cost paid		(343,701,541)			(343,701,541)		(132,661,492)		•	(132,661,492)
Musharaka received				90,002,620	90,002,620				91,192,200	91,192,200
Musharaka paid				(22,915,341)	(22,915,341)				•	
Total changes from financing cash flows	(126,194,628)	(343,701,541)	22,744,364	67,087,279	(380,064,526)	(265,619)	(132,661,492)	(20,343,525)	91,192,200	(62,078,436)
<u>Non-cash changes</u>										
Dividend approved	130,407,156		•		130,407,156			•		•
Interest / markup expense		275,783,784			275,783,784		180,756,913			180,756,913
Total non-cash changes	130,407,156	275,783,784	•		406,190,940		180,756,913			180,756,913
Balance as at 31 December	100,719,891	104,397,591	204,209,289	235,804,426	645,131,197	97,067,088	90,235,877	108,582,401	91,192,200	387,077,566

Financial risk management and fair value of financial instruments

The Company's financial risk management objective and policies are consistent with that disclosed in the annual unconsolidated financial statements of the Company for the year ended 30 June 2024. 18.1

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value. 18.2

		Carrying Amount	Amount			Fair Value	
	Fair value through statement of profit or loss	Financial assets at amortised cost	Other financial liabilities	Total	Level 1	Level 2	Level 3
31 December 2024 (Un-audited)				- Rupees			
Financial assets measured at fair value:	2,667,104,079			2,667,104,079	2,667,104,079		
Financial assets not measured at fair value							
Long term deposits		9,922,000		9,922,000			٠
Trade debts		2,580,231,777	•	2,580,231,777		•	•
Loans and advances		50,656,030		50,656,030			
Deposits and prepayments		190,390,110	•	190,390,110		•	•
Other receivables		84,841,588		84,841,588			
Bank balances		317,364,647		317,364,647			
		3,233,406,152		3,233,406,152			
Financial liabilities measured at fair value	,	•	-	-	1	•	1
Financial liabilities not measured at fair value							
Trade and other payables			2,475,905,927	2,475,905,927		•	
Unclaimed dividend			100,719,891	100,719,891			
Long term loans - secured			148,898,334	148,898,334			
Long term musharaka - secured			235,804,426	235,804,426			
Short term borrowings - secured			4,518,863,364	4,518,863,364			•
Accrued mark-up	•		104,397,591	104,397,591	•	•	•
	•		7.584.589.533	7.584.589.533			

		Carrying Amount	Amount			Fair Value	
	Fair value through statement of profit or loss	Financial assets at amortised cost	Other financial liabilities	Total	Level 1	Level 2	Level 3
30 June 2024 (Audited)				Rupees			
Financial assets measured at fair value:	375,541,979	·	,	375,541,979	375,541,979	1	,
Financial assets not measured at fair value							
Long term deposits	ı	9,777,325	ı	9,777,325	1	1	ı
Trade debts	•	2,199,853,473	ı	2,199,853,473	1	1	1
Loans and advances	•	13,686,361	1	13,686,361	1	1	ı
Deposits and prepayments	•	173,693,929	1	173,693,929	1	1	ı
Other receivables	•	58,626,606	•	58,626,606		1	1
Bank balances	•	268,898,922		268,898,922	1	ı	ı
	1	2,724,536,616	1	2,724,536,616	-	1	1
Financial liabilities measured at fair value:		,	,	,			'
Financial liabilities not measured at fair value							
Trade and other payables	1	1	1,413,656,892	1,413,656,892	1	1	ı
Unclaimed dividend	•	•	96,507,363	96,507,363	1	1	1
Long term loans - secured	•	1	124,392,873	124,392,873	1	1	1
Long term musharaka - secured	•	ı	168,717,147	168,717,147			
Short term borrowings - secured	•	ı	2,407,658,889	2,407,658,889	1	1	1
Accrued mark-up	•	ı	172,315,348	172,315,348	1	1	1
		1	4,383,248,512	4,383,248,512		1	1

19 Subsequent event

The	Board	of I	Directors	of	the	Company	in	its	meeting	held	on	28	February	2025	has	approv	ved ar
inte	rim casl	h div	idend of	Rs.	. Nil	per share	(31	De	ecember 2	2023:	Rs	. Ni	l per share	e), am	ounti	ing to I	Rs. Ni
(31	Decem	ber 2	023: Rs.	Nil	l) fo	r the year ϵ	end	ing	30 June	2025.							

20 General

Figures have been rounded off to nearest rupee.

Date of authorization for issue 21

These	un-audited	condensed	interim	unconsolidated	financial	statements	were	authorized	for	issue	by
the Bo	oard of Dire	ctors of the	Compar	ny on 28 Februar	ry 2025.						

Chief Executive Officer	Chief Financial Officer	Director





CONSOLIDATED FINACIAL STATEMENTS

Limited	
Laboratories	
Ferozsons]	

Condensed Interim Consolidated Statement of Financial Position

As at 31 December 2024

		Un-audited 31 December 2024	Audited 30 June 2024			Un-audited 31 December 2024
EQUITY AND LIABILITIES	Note	Rupees	S	ASSETS	Note	Rupe
Share capital and reserves. Authorized share capital 150,000,000 (30 June 2024: 150,000,000) ordinary shares of Rs. 10 each	"	1,500,000,000	1,500,000,000	Non-current assets Property, plant and equipment Intangible assets Investment property Long term deposits		11,846,369,337 37,124,455 79,371,992 17,749,000
Issued, subscribed and paid up capital Capital reserve Revaluation surplus on property, plant and equipment Accumulated profits Equity attributable to owners of the Company	1	434,690,520 321,843 3,648,453,902 7,886,599,050 11,970,065,315	434,690,520 321,843 3,753,246,119 7,040,048,601 11,228,307,083	Current assets Stores, spare parts and loose tools		11,980,614,784
Non-controlling interests Non current liabilities	ı	1,993,481,104	591,877,248 11,820,184,331	Stock in trade Trade debts Loans and advances - considered good Deposits and prepayments Other receivables - considered good		5,698,366,336 2,879,928,397 418,563,730 250,375,796 275,841,988
Long term loans - <i>secured</i> Long term musharaka - secured Deferred grant Deferred taxation	4	1,580,614,895 261,442,794 415,474,174 1,496,834,424 3,754,366,287	1,699,776,488 143,830,767 476,905,461 1,523,995,187 3,844,507,903	Advance income tax - ner Short tern investments Cash and bank balances	∞ 6	591,250,810 4,553,079,542 505,621,374 15,429,586,182
Current liabilities Current portion of:	L					
- Long term loans - secured - Long term musharaka - secured - Deferred grant Trade and other payables Contract labilities	4	326,827,466 56,356,854 133,952,262 3,906,434,628 263,472,085	308,184,628 24,886,380 138,213,359 2,235,066,200 333,057,621			
Short tern borrowings - <i>secured</i> Unclaimed dividend Accrued mark-up	ĸ	4,760,948,233 100,719,891 143,576,841 9,692,288,260	2,743,034,136 96,507,363 205,979,682 6,084,929,369			
Contingencies and commitments	9	27,410,200,966	21,749,621,603		1 11	27,410,200,966

11,828,402,182 41,038,671 79,371,992 17,604,325 11,966,417,170

Audited 30 June 2024

---- Rupees

196,313,491 4,781,368,229 2,416,614,379 211,128,888 333,433,703 283,807,115 512,978,990 496,495,295 551,064,343 9,783,204,433

The annexed notes from 1 to 16 form an integral part of these condensed interim consolidated financial statements.

Chief Financial Officer Chief Executive Officer

Director

Ferozsons Laboratories Limited

Condensed Interim Consolidated Statement of Profit or Loss (Un-audited)

For the half year and quarter ended 31 December 2024

		Half year	· ended	Quarter	ended
		31 December 2024	31 December 2023 Restated	31 December 2024	31 December 2023 Restated
	Note	Rup	ees	Rup	ees
Revenue - net	10	9,259,937,017	8,298,817,623	4,730,951,335	3,870,276,446
Cost of sales	11	(5,317,218,885)	(5,104,541,690)	(2,641,235,449)	(2,395,347,170)
Gross profit		3,942,718,132	3,194,275,933	2,089,715,886	1,474,929,276
Administrative expenses		(466,195,315)	(384,750,927)	(240,765,255)	(180,339,934)
Selling and distribution expenses		(2,441,529,678)	(1,917,066,589)	(1,388,895,764)	(952,602,260)
Other expenses		(100,447,885)	(174,469,433)	(52,768,925)	(134,280,383)
Other income		118,648,391	142,700,531	91,576,790	65,696,621
Profit from operations		1,053,193,645	860,689,515	498,862,732	273,403,320
Finance cost		(365,394,089)	(256,031,730)	(171,485,876)	(134,959,033)
Profit before income tax, final tax and					
minimum tax differential		687,799,556	604,657,785	327,376,856	138,444,287
Minimum tax differential		(13,643,912)	(3,063,548)	(5,504,140)	819,094
Final tax			(8,048,610)	5,289,845	(1,209,319)
Profit before income tax		674,155,644	593,545,627	327,162,561	138,054,062
Income tax		(255,584,535)	(200,446,526)	(149,611,828)	(26,423,605)
Profit after taxation		418,571,109	393,099,101	177,550,733	111,630,457
Attributable to:					
Owners of the Group		370,849,647	364,989,221	150,454,296	101,889,167
Non-controlling interests		47,721,462	28,109,880	27,096,437	9,741,290
Profit after taxation		418,571,109	393,099,101	177,550,733	111,630,457
Comings now shows the six and diluted		0.50	0.40	2.44	2.24
Earnings per share - basic and diluted		8.53	8.40	3.46	2.34

The annexed notes from 1 to 16 form an integral part of these condensed interim consolidated financial statements.

		
Chief Executive Officer	Chief Financial Officer	Director

Ferozsons Laboratories Limited

Condensed Interim Consolidated Statement of Comprehensive Income (Un-audited)

For the half year and quarter ended 31 December 2024

	Half yea	r ended	Quarter	ended
	31 December	31 December	31 December	31 December
	2024	2023	2024	2023
	Rup	ees	Rup	ees
Profit after taxation	418,571,109	393,099,101	177,550,733	111,630,457
Other comprehensive income for the period	-	-	-	-
Total comprehensive income for the period	418,571,109	393,099,101	177,550,733	111,630,457
Attributable to:				
Owners of the Group	370,849,647	364,989,221	150,454,296	101,889,167
Non-controlling interests	47,721,462	28,109,880	27,096,437	9,741,290
	418,571,109	393,099,101	177,550,733	111,630,457

Τ	'he annexed	notes f	from 1	l to i	16	form a	n integral	part of	these	condense	d interim	consolid	lated	financia	statements	ŝ.

Chief Executive Officer	Chief Financial Officer	Director

Ferozsons Laboratories Limited Condensed Interim Consolidated Statement of Changes in Equity (Un-audited) For the half year ended 31 December 2024

7	Attributable to O	Attributable to Owners of the Company	,			
	Capit	Capital reserve	Revenue reserve			
Share capital	Capital reserve	Revaluation surplus on property, plant and equipment	Accumulated profits	Total	Non-controlling interest	Total
434,690,520	321,843	1,193,114,683	Rupees	7,918,111,468	445,453,599	8,363,565,067
	. '		364,989,221	364,989,221	28,109,880	393,099,101
		(23,182,554)	23,182,554			
434,690,520	321,843	1,169,932,129	6,678,156,197	8,283,100,689	473,563,479	8,756,664,168
434,690,520	321,843	3,753,246,119	7,040,048,601	11,228,307,083	591,877,248	11,820,184,331
	•		370,849,647	370,849,647	47,721,462	418,571,109
		(104,792,217)	104,792,217			•
			(130,407,156)	(130,407,156)	- 1855 108 135	(130,407,156)
			501,315,741	501,315,741	(501,315,741)	-
434.690.520	321.843	3,648,453,902	7.886.599.050	11.970.065.315	1.993,481,104	13.963.546.419

on account of incremental depreciation on property, plant and equipment charged during the period - net of tax

Total comprehensive income for the period

Balance as at 01 July 2023

Surplus transferred to accumulated profit:

Balance as at 31 December 2023 - un-audited

Total comprehensive income for the period

Balance as at 01 July 2024

Surplus transferred to accumulated profit:

The annexed notes from 1 to 16 form an integral part of these condensed interim consolidated financial statements.

Director

on account of incremental depreciation on property, plant and equipment charged during the period - net of tax

Transactions with owners of the Company, recognized directly in equity - distributions - final dividend for the year ended 30 June 2024 at Rs. 3 per share

issuance of new shares by subsidiary to NCI net of transaction cost
 effect of change in ownership without loss of control

Balance as at 31 December 2024 - un-audited

Condensed Interim Consolidated Statement of Cash Flows (Un-audited)	Half year o	anded
For the half year ended 31 December 2024	31 December	31 December
	2024	2023 Restated
Cash flow from operating activities	Rupee	s
Profit after taxation Adjustments for non - cash and other items	418,571,109	393,099,101
Depreciation on property, plant and equipment	403,332,630	249,231,632
Amortization of intangible assets	9,035,846	10,525,158
Provision of loss allowance against trade debts Gain on disposal of property, plant and equipment	27,311,572 (6,533,359)	111,268,345 (17,772,784)
Finance costs	363,265,372	256,031,730
Gain on re-measurement of short term investments to fair value	(82,199,753)	(37,551,385)
Gain on sale of short term investments	-	(317,789)
Dividend income Minimum tax	(28,565) 13,643,912	(13,474,772) 3,063,548
Final tax	-	8,048,610
Income tax	255,584,535	200,446,526
Profit on deposits with bank	(21,259,755)	(5,955,534)
Workers' Profit Participation Fund Central Research Fund	41,809,316	39,949,609 8,070,628
Workers' Welfare Fund	8,016,283 17,731,236	15,180,851
	1,029,709,270	826,744,373
Cash generated from operations before working capital changes	1,448,280,379	1,219,843,474
Effect on cash flow due to working capital changes (Increase) / decrease in current assets		
Stores, spare parts and loose tools	(60,244,718)	(8,459,327)
Stock in trade	(916,998,107)	(271,225,466)
Trade debts Loans and advances - considered good	(490,625,590) (207,434,842)	(1,236,962,818) (332,986,381)
Deposits and prepayments	83,057,907	(108,154,950)
Other receivables	7,965,127	(4,481,297)
In the second of	(1,584,280,223)	(1,962,270,239)
Increase / (decrease) in current liabilities Trade and other payables	1,659,293,592	137,371,123
Contract liabilities	(69,585,536)	85,354,636
Cash generated from / (used in) operations	1,453,708,212	(519,701,006)
Income tax paid	(361,017,118)	(166,426,881)
Minimum Tax paid Final Tax paid	(13,643,912)	(2,150,724) (4,828,050)
Workers' Profit Participation Fund paid	(42,541,527)	(13,680,252)
Central Research Fund paid	(12,940,472)	(5,187,240)
Net cash generated from / (used in) operating activities	1,023,565,183	(711,974,153)
Cash flow from investing activities		
Acquisition of property, plant and equipment	(422,753,166)	(182,598,846)
Acquisition of intangibles Dividend income received	(5,121,630) 28,565	(60,501,000) 9,150,444
Proceeds from sale of property, plant and equipment	7,986,741	23,443,897
Long term deposit - net	(144,675)	(3,000,000)
Profit on term deposits received Short term investments - net	21,259,755 (3,974,384,494)	5,955,534 87,229,890
Net cash used in investing activities	(4,373,128,904)	(120,320,081)
Cash flow from financing activities		
Subscription money received against IPO - net of Transaction cost	1,855,198,135	-
Long term musharaka received	183,554,428	-
Long term musharaka paid	(34,471,927)	-
Long term loan received Long term loan paid	32,374,000 (213,789,002)	91,192,200 (170,800,953)
Finance cost paid	(410,464,351)	(219,918,016)
Dividend paid	(126,194,628)	(265,619)
Net cash generated from / (used in) financing activities	1,286,206,655	(299,792,388)
Net decrease in cash and cash equivalents Cash and cash equivalents at the beginning of the period	(2,063,357,066)	(1,132,086,622)
Cash and cash equivalents at the beginning of the period	(2,191,969,793) (4,255,326,859)	(691,494,844) (1,823,581,466)
Cash and cash equivalents comprise of the following:		
Cash and bank balances	505,621,374	553,106,858
Running finance	$\frac{(4,760,948,233)}{(4,255,326,859)}$	(2,376,688,324) (1,823,581,466)

Ferozsons Laboratories Limited

Notes to the Condensed Interim Consolidated Financial Statements (Un-audited)

For the half year ended 31 December 2024

The Group and its operation

Ferozsons Laboratories Limited ("the Holding Company") was incorporated as a private limited company on 28 January 1954 and commenced its commercial operations in 1956. The Company was converted into a public limited company on 08 September 1960. The Holding Company is listed on the Pakistan Stock Exchange Limited and is primarily engaged in the imports, manufacture and sale of pharmaceuticals products and medical devices. Its registered office is situated at 197-A, The Mall, Rawalpindi and the manufacturing facility is located at Amangarh, Nowshera, Khyber Pakhtoon Khwa.

"The Group" consists of the following subsidiaries:

			Effective h	olding %
Company / Entity	County of incorporation	Nature of business	31 December 2024	30 June 2024
BF Biosciences Limited	Pakistan	Import, manufacturing and sale of pharmaceutical products	57.36	80
Farmacia	Pakistan	Sale and distribution of medicines and other related products	98	98

The registered office of the BF Biosciences Limited is situated at 197-A, The Mall, Rawalpindi and the production facility is located at 5 KM- Sunder Raiwind Road Lahore. The head office of the Farmacia is situated at Fatima Memorial Hospital, Shadman, Lahore.

During the period ended 31 December 2024, BF Biosciences Limited issued 25,000,000 new shares to noncontrolling shareholders for a total consideration of Rs. 1,855,198,135 (net of transaction cost). As a result, the Holding Company's ownership in BF Biosciences Limited decreased from 80% to 57.36%. Since the Holding Company retained control, this transaction was accounted for as an equity transaction under IFRS 10 and did not impact profit or loss.

Basis of consolidation

These consolidated financial information includes the financial statements of Ferozsons Laboratories Limited and its subsidiaries - BF Biosciences Limited and Farmacia ("hereinafter referred as the Group").

Subsidiaries are those entities, including an unincorporated entities such as a partnership that are controlled by another entity (known as the parent). The financial statements of the subsidiaries are included in the consolidated financial information from the date, the control commences, until the date when that control ceases. The financial statements of the subsidiaries have been consolidated on line by line basis. Details of the subsidiaries are given in Note

All material inter-organization balances, transactions and resulting unrealized profits / losses have been eliminated.

3 **Basis of preparation**

3.1 Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan. The accounting and reporting standards applicable in Pakistan comprise of:

- International Financial Reporting Standards (IFRS Standards) issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017; and
- Islamic Financial Accounting Standards (IFAS) issued by the Institute of Chartered Accountants of Pakistan as notified under the Companies Act, 2017; and
- Provisions of and directives issued under the Companies Act, 2017.

Where provisions of and directives issued under the Companies Act, 2017 differ from the IFRS Standards, the provisions of and directives issued under the Companies Act, 2017 have been followed.

3.2 **Basis of accounting**

- 3.2.1 This condensed interim consolidated financial information comprises the condensed interim consolidated statement of financial position of the Holding Company, as at 31 December 2024 and the related condensed interim consolidated statement of profit or loss, condensed interim consolidated statement of comprehensive income, condensed interim consolidated statement of changes in equity and condensed interim consolidated statement of cash flows together with the notes forming part thereof.
- 3.2.2 This condensed interim consolidated financial information do not include all of the information required for annual financial statements, and should be read in conjunction with the consolidated financial statements of the Holding Company as at and for the year ended 30 June 2024.

- 3.2.3 Comparative consolidated statement of financial position's numbers are extracted from the annual audited consolidated financial statements of the Holding Company for the year ended 30 June 2024, whereas comparative consolidated statement of profit or loss, statement of comprehensive income, statement of changes in equity and statement of cash flows are stated from unaudited condensed interim consolidated financial statements of the Holding Company for the six months period ended 31 December 2023.
- This condensed interim consolidated financial information is unaudited and being submitted to the 3.2.4 shareholders as required under Section 237 of the Companies Act, 2017 and the Listing Regulations of the Pakistan Stock Exchange Limited.

3.3 Judgements and estimates

In preparing this interim consolidated financial information, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgments made by the management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 30 June 2024.

3.4 Statement of consistency in accounting policies

3.4.1 The accounting policies and the methods of computation adopted in the preparation of this condensed interim consolidated financial information are same as those applied in the preparation of the annual audited consolidated financial statements for the year ended 30 June 2024.

There were certain other new standards and amendments to the approved accounting standards which became effective during the period but are considered not to be relevant or have any significant effect on the Group's operations and are, therefore, not disclosed.

Long term musharaka - secured

There is no change in the sanctioned limits as already disclosed in the annual consolidated financial statements for the year ended 30 June 2024 except for the new long term musharaka which has been obtained by the Subsidiary Company during the period as mentioned below:

The Subsidiary Company, BF Biosciences Limited obtained financing facility under "Diminishing Musharaka" from First Habib Modaraba amounting to Rs. 81.99 million for the purpose of purchase of vehicles.

Short term borrowings - secured

All terms and conditions applicable on short term borrowings availed are same as those disclosed in the annual consolidated financial statements for the year ended 30 June 2024 except for the new short-term loans obtained by the Holding Company during the period under Shariah-compliant arrangements and mark-up arrangements, amounting to Rs. 3,000 million and Rs. 1,229 million, respectively. These short-term loans carry a profit/mark-up ranging from KIBOR minus 2.75% to KIBOR minus 3%.

Contingencies and commitments

There is no significant change in the status of the contingencies and commitments as reported in the annual audited consolidated financial statements for the year ended 30 June 2024.

			Un-audited 31 December 2024 Rupe	Audited 30 June 2024
7	Property, plant and equipment	Note		
	Operating fixed assets Capital work-in-progress	7.1	11,548,710,911 297,658,426 11,846,369,337	8,119,903,488 3,708,498,694 11,828,402,182
	7.1 Operating fixed assets			
	Cost			
	Opening balance at beginning of the period / year Additions / transfers during the period / year Revaluation surplus - net Disposals during the period / year Closing balance at end of the period / year		8,781,321,507 3,833,593,433 - (18,454,465) 12,596,460,475	5,329,009,563 996,038,526 2,596,731,941 (140,458,523) 8,781,321,507
	Less: Accumulated depreciation			
	Opening balance at beginning of the period / year Depreciation for the period / year Elimination of accumulated depreciation on revaluation On disposals Closing balance at end of the period / year		661,418,019 403,332,628 - (17,001,083) 1,047,749,564	1,514,252,015 517,090,795 (1,283,113,977) (86,810,814) 661,418,019
	Operating fixed assets - net book value		11,548,710,911	8,119,903,488

			Note	Un-audited 31 December 2024Rupe	Audited 30 June 2024
Short	t term investments				
Inves	tments at fair value through profit or loss				
Mutu	al fund		8.1	4,553,079,542	496,495,295
8.1	These investments are measured at 'fair value through Profi	t or Loss'			
	Fair value at 01 July			496,495,295	544,965,655
	Dividend re-invested during the period / year			28,565	64,119,128
	Acquistion / (Redemption) during the period / year - net			3,981,234,871	(168,701,582)
	Realized gain on sale of investments during the period / year			-	6,390,555
	Unrealized gain on re-measurement of investment during th	ne period / year		75,320,811	49,721,539
	Fair value at 31 December / 30 June		8.1.1	4,553,079,542	496,495,295
				F-:	
		Unit	S	rair v	alue
		Unit Un-audited	Audited	Fair v	Audited
		Un-audited	Audited	Un-audited	Audited
		Un-audited 31 December	Audited 30 June 2024	Un-audited 31 December 2024	Audited 30 June 2024
8.1.1	Mutual fund wise detail is as follows:	Un-audited 31 December 2024	Audited 30 June 2024	Un-audited 31 December 2024	Audited 30 June 2024
8.1.1	Mutual fund wise detail is as follows: HBL Money Market Fund	Un-audited 31 December 2024	Audited 30 June 2024	Un-audited 31 December 2024	Audited 30 June 2024
8.1.1		Un-audited 31 December 2024Numb	Audited 30 June 2024 per	Un-audited 31 December 2024Rupe	Audited 30 June 2024
8.1.1	HBL Money Market Fund	Un-audited 31 December 2024Numb	Audited 30 June 2024 per	Un-audited 31 December 2024Rupe	Audited 30 June 2024 ees
8.1.1	HBL Money Market Fund HBL Cash Fund ABL Cash Fund Pakistan Cash Management Fund	Un-audited 31 December 2024Numb 3,367,379 17,041,659 28,591,251 12,673	Audited 30 June 2024 Der	Un-audited 31 December 2024Rupe 378,252,348 1,941,147,870 319,152,704 489,981	Audited 30 June 2024 ees
8.1.1	HBL Money Market Fund HBL Cash Fund ABL Cash Fund Pakistan Cash Management Fund UBL Money Market Fund	Un-audited 31 December 2024Numb 3,367,379 17,041,659 28,591,251 12,673 1,852,607	Audited 30 June 2024 ber	Un-audited 31 December 2024Rupe 378,252,348 1,941,147,870 319,152,704 489,981 203,329,453	Audited 30 June 2024 2025 348,467,577 51,944,030 12,555,825
8.1.1	HBL Money Market Fund HBL Cash Fund ABL Cash Fund Pakistan Cash Management Fund UBL Money Market Fund Alfalah Money Market Fund	Un-audited 31 December 2024Numb 3,367,379 17,041,659 28,591,251 12,673 1,852,607 5,666,534	Audited 30 June 2024 ber	Un-audited 31 December 2024Rupe 378,252,348 1,941,147,870 319,152,704 489,981 203,329,453 610,771,889	Audited 30 June 2024 2025 348,467,577 51,944,030 12,555,825
8.1.1	HBL Money Market Fund HBL Cash Fund ABL Cash Fund Pakistan Cash Management Fund UBL Money Market Fund Alfalah Money Market Fund Alfalah Cash Fund	Un-audited 31 December 2024Numb 3,367,379 17,041,659 28,591,251 12,673 1,852,607 5,666,534 19	Audited 30 June 2024 Der	Un-audited 31 December 2024Rupe 378,252,348 1,941,147,870 319,152,704 489,981 203,329,453 610,771,889 10,186	Audited 30 June 2024 2025 348,467,577 51,944,030 12,555,825 473,030
8.1.1	HBL Money Market Fund HBL Cash Fund ABL Cash Fund Pakistan Cash Management Fund UBL Money Market Fund Alfalah Money Market Fund	Un-audited 31 December 2024Numb 3,367,379 17,041,659 28,591,251 12,673 1,852,607 5,666,534	Audited 30 June 2024 Der	Un-audited 31 December 2024Rupe 378,252,348 1,941,147,870 319,152,704 489,981 203,329,453 610,771,889	Audited 30 June 2024 2025 348,467,577 51,944,030 12,555,825

9 Cash and bank balances

8

- 9.1 These include current account of Rs. 0.097 million (30 June 2024: Rs. 25.71 million) maintained under Shariah compliant arrangements.
- 9.2 These include deposit accounts of Rs. 10.78 million (30 June 2024: Rs. 23.05 million) under mark up arrangements, which carry interest rates ranging from 10.00% to 20.50% (30 June 2024: 19.02% to 20.51%) per annum.

These also include deposit account of Rs. 3.83 million (30 June 2024: Rs. 0.71 million) under Shariah compliant arrangements, which carries profit rate ranging from 5.87% to 11.01% (30 June 2024: 10.00% to 11.01%) per annum.

4,553,079,542

496,495,295

			•	(Un-audited) Ha	alf year ended
			·	31 December 2024	31 December 2023
			Note	Rupe	ees
10	Rever	nue - net			
	Gross	sales:			
	Loc	cal		10,080,741,811	8,932,904,923
	Exp	port		582,981,910	446,870,702
				10,663,723,721	9,379,775,625
	Less:				
		les returns		(74,738,800)	(110,895,397)
		scounts		(1,260,227,413)	(909,535,348)
	Sal	les tax		(68,820,491)	(60,527,257)
	ъ.		10.1	(1,403,786,704)	(1,080,958,002)
	Rever	nue from contracts with customers	10.1	9,259,937,017	8,298,817,623
	10.1	Disaggregation of Revenue (Net sales)			
		Primary Geographical Markets:			
		Pakistan		8,676,955,107	7,851,946,922
		Sri Lanka		125,185,244	159,748,547
		Afghanistan		261,698,977	157,764,768
		Philippines		69,648,948	44,644,781
		Kenya		21,501,314	29,135,294
		Nepal		22,238,994	17,117,398
		Kyrgyzstan		16,505,216	17,017,604
		Myanmar		44,695,948	14,698,310
		Others		21,507,269	6,743,999
			:	9,259,937,017	8,298,817,623
1	Cost	of sales			
	Raw a	and packing materials consumed	11.1	2,818,493,146	2,488,123,495
	Other	manufacturing expenses		1,388,622,840	1,034,604,017
	117I.	•		4,207,115,986	3,522,727,512
		in process: ening		423,548,791	249,627,985
	-	esing		(529,706,505)	(352,599,048)
	Cio	Sing		(106,157,714)	(102,971,063)
	Cont	of acode manufactured		4,100,958,272	3,419,756,449
		of goods manufactured		4,100,958,272	3,419,730,449
		ned stock:		2 202 000 111	1 225 004 400
	-	ening		2,392,888,111	1,325,994,498
		chases made during the period		1,329,686,530	3,049,306,514
	Clo	sing		(2,506,314,028)	(2,690,515,771)
				1,216,260,613 5,317,218,885	1,684,785,241 5,104,541,690
			:	3,317,210,003	3,104,341,070
	11.1	Raw and packing materials consumed			
		Opening		1,752,978,969	1,832,285,298
		Purchases made during the period		2,796,092,617	2,678,447,284
		commo emo ponico		4,549,071,586	4,510,732,582
		Closing		(1,730,578,440)	(2,022,609,087)
				2,818,493,146	2,488,123,495
			:	_,010,120,170	_, . 50, 125, 175

Related party transactions

The Group's related parties include associated companies, entities over which directors are able to exercise influence, staff retirement fund, directors and key management personnel. Transactions with related parties are as follows:

			(Un-audited) Half year ended	ılf year ended
Name of parties	Relationship	Transactions	31 December 2024	31 December 2023
			Rs	
Bago Laboratories Pte. Limited	Associated Company	Purchase of medicine Payment made against purchase of medicine	8,464,593 12,678,206	44,648,569 94,182,434
Employees Provident Fund	Post employment benefit fund	Contribution towards employees' provident fund	52,648,626	48,585,958
Key Management Personnel	Key management personnel	Remuneration including benefits and perquisites Advance given against salary Cash dividend	48,905,632	27,263,565 1,931,316
KFW Factors (Private) Limited	Common directorship	Cash dividend Share of profit of Farmacia reinvested	35,799,582 273,645	196,598
Osman Khalid Waheed	Chief Executive Officer-Holding Company	Remuneration including benefits and perquisites Cash Dividend Advance given against salary Meeting fee	33,824,349 10,208,241 500,000 110,000	26,293,552 - 20,000
Akhtar Khalid Waheed	Chief Executive Officer-Subsidiary Company	Meeting fee Cash Dividend	200,000 15,000	20,000
Directors other than CEOs	Non-Executive Directors	Cash Dividend Reimbursement of expenses Meeting fee Rental expense paid for building in use	3,341,034 87,000 2,350,000 2,816,781	- 160,000 2,995,549
Khan and Piracha	Common directorship	Payment made against services received	390,000	1
Lahore Biennale Foundation (LBF)	Common directorship	Donation	2,500,000	1
National Management Foundation / (LUMS)	Common directorship	Donations Event sponsorship	500,000	5,000,000

Reconciliation of movement of liabilities to cash flows arising from financing activities 13

		31]	31 December 2024 (Un-audited)	udited)			31 December 2	31 December 2023 (Un-audited)	
	Unclaimed dividend	Accrued mark-up	Long term loans and musharaka - secured	Subscription money received against IPO	Total	Unclaimed dividend	Accrued mark-up	Long term loans and musharaka - secured	Total
As at 01 July	96,507,363	205,979,682	Rupees 779,682 2,791,797,084		3,094,284,129	97,332,707	85,967,950	Rupees 85,967,950 2,891,898,383	3,075,199,040
Changes from financing cash flows									
Dividend paid	(126,194,628)				(126,194,628)	(265,619)			(265,619)
Musharaka received			183,554,428		183,554,428	•	ı	91,192,200	91,192,200
Musharaka paid			(34,471,927)		(34,471,927)			•	
Repayment of long term loan			(213,789,002)		(213,789,002)	1	ı	(170,800,953)	(170,800,953)
Proceeds from long term loan			32,374,000		32,374,000	•	ı	•	,
Subscription money received against IPO				1,855,198,135	1,855,198,135	•	ı		,
Finance cost paid		(410,464,351)			(410,464,351)		(219,918,016)	٠	(219,918,016)
Total changes from financing cash flows	(126,194,628)	(410,464,351)	(32,332,501)	1,855,198,135	1,286,206,655	(265,619)	(219,918,016)	(79,608,753)	(299,792,388)
Other changes									
Dividend approved	130,407,156				130,407,156		•		•
Issuance of Shares				(1,855,198,135)	(1,855,198,135)	•	ı	•	
Impact of effective rate		(15,203,862)	15,203,862			•	•	•	•
Interest / markup expense		363,265,372			363,265,372		256,031,730		256,031,730
Total liability related other changes	130,407,156	348,061,510	15,203,862	(1,855,198,135)	(1,361,525,607)	•	256,031,730	•	256,031,730
As at 31 December	100,719,891	143,576,841	2,774,668,445		3,018,965,177	97,067,088	122,081,664	2,812,289,630	3,031,438,382

Financial risk management and financial instruments - fair value 4

The Group's financial risk management objective and policies are consistent with that disclosed in the annual consolidated financial statements of the Holding Company for the year ended 30 June 2024. The exposure to credit risk relates to trade and other receivables which are majorly due from Government institutions and the Group does not expect these institutions to fail to meet their obligations. 14.1

14.2 The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

Pair Value through statement at profit or local maneritard cost of m			Carryin	g Amount			Fair Value	
Primacial assets measured at fair value:		statement of profit	Financial assets at amortized cost	Other financial liabilities			Level 2	
	31 December 2024 (Un-audited)				Rupees			
Financial assets and measured at fair value: Ing term deposits	Financial assets measured at fair value:							
17,749,000	Short term investments	4,553,079,542	-		4,553,079,542	4,553,079,542		-
Track delses - considered good 2,879.938,97 2,579.938,97	Financial assets not measured at fair value:							
Sect Continue deposits \$2,02,3,023 \$2,02,3,023 \$2,02,3,023 \$2,02,19,871 \$2,02,19,8	Long term deposits		17,749,000		17,749,000			
Soft net deposits 220,219,871 20,229,871	Trade debts - considered good		2,879,928,397	-	2,879,928,397	-	-	-
Clast and bank balances 67864,777 67,864,777	Loans and advances - considered good		52,023,023	-	52,023,023	-	-	-
Sils.501.374	Short term deposits		220,219,871	-	220,219,871	-	-	-
Transcial liabilities measured at fair value:	Other receivables		67,864,777	-		-	-	-
Financial liabilities measured at fair value: Financial liabilities not measured at fair value: Trade and other payables 3,601,094,643 3,601,094,643 100,719,891 100,719,891 100,719,891 100,719,891 100,719,891 100,719,891 100,719,891 100,719,891 100,719,891 100,719,891 100,719,891 100,719,891 100,719,948 143,576,841 143,576,8	Cash and bank balances		505,621,374	-	505,621,374	-	-	-
Financial liabilities not measured at fair value:			3,743,406,442	•				-
Trade and other payables	Financial liabilities measured at fair value:		•		<u> </u>	•	-	-
Unclaimed dividend	Financial liabilities not measured at fair value:							
Unclaimed dividend	Trade and other payables			3,601,094,643	3,601,094,643			
Long term musharaka - secured 317,799,648 317,799,648 1.0	Unclaimed dividend		-		, , ,		-	-
Consider	Long term musharaka - secured		-					
Note term borrowings - secured 1,4760,948,233 1,760,948,233 1,381,008,053 1,381,008,			-	2,456,868,797				
Accrued mark-up		-	-	4,760,948,233				
Trade and other payables St. Schort em resurred at fair value: Short term deposits 17,604,325 17,60	-			143,576,841				
Short term investments 496,495,295 - - 496,495,295 496,495,295 - - -		-		11,381,008,053	11,381,008,053			-
Short term investments	30 June 2024 (Audited)							
Long term deposits	Financial assets measured at fair value:							
Long term deposits	Short term investments	496,495,295	-	-	496,495,295	496,495,295	-	<u> </u>
Trade debts - considered good 2,416,614,379 2,416,614,379	Financial assets not measured at fair value:							
Trade debts - considered good 2,416,614,379 2,416,614,379	Long term deposits		17,604,325		17,604,325			
Loans and advances - considered good 13,686,361 13,686,361								-
Short term deposits	· ·					-		
Other receivables - 58,626,606 - 58,626,606 -	Short term deposits				322,041,020			
- 3,379,637,034	Other receivables		58,626,606	-	58,626,606		-	-
- 3,379,637,034	Cash and bank balances	-	551,064,343	-	551,064,343	-	-	-
Financial liabilities not measured at fair value: Trade and other payables - 1,977,368,796 1,977,368,796 - - - Unclaimed dividend - 96,507,363 96,507,363 - - - Long term loans - secured - 2,007,961,116 2,007,961,116 - - - Long term musharaka - secured - 168,717,147 168,717,147 - - - Short term borrowings - secured - 2,743,034,136 2,743,034,136 - - - Accrued mark-up - 205,979,682 205,979,682 - - - -		-		-		-	-	-
Trade and other payables - 1,977,368,796 1,977,368,796 - - - Unclaimed dividend - 96,507,363 96,507,363 - - - Long term loans - secured - 2,007,961,116 2,007,961,116 - - - Long term musharaka - secured - 168,717,147 - - - Short term borrowings - secured - 2,743,034,136 2,743,034,136 - - - Accrued mark-up - 205,979,682 205,979,682 - - - - -	Financial liabilities measured at fair value:	-	-	-		<u>-</u>	-	-
Unclaimed dividend - - 96,507,363 96,507,363 -	Financial liabilities not measured at fair value:							
Long term loans - secured - 2,007,961,116 2,007,961,116 - - - Long term musharaka - secured - 168,717,147 168,717,147 - - - Short term borrowings - secured - 2,743,034,136 2,743,034,136 - - - Accrued mark-up - 205,979,682 205,979,682 - - - -	Trade and other payables	-	-	1,977,368,796	1,977,368,796	-	-	-
Long term musharaka - secured - - 168,717,147 - - - Short term borrowings - secured - - 2,743,034,136 - - - - Accrued mark-up - - 205,979,682 205,979,682 - - - - -		-	-	96,507,363	96,507,363	-	-	-
Short term borrowings - secured - - 2,743,034,136 - - - - Accrued mark-up - - 205,979,682 205,979,682 - - - - -	Long term loans - secured	-	-	2,007,961,116	2,007,961,116	-	-	-
Accrued mark-up - 205,979,682 205,979,682		-	-	168,717,147	168,717,147	-	-	-
		-	-			-	-	-
7,199,568,240	Accrued mark-up	-	-			-	-	-
		-	-	7,199,568,240	7,199,568,240	-	-	-

15 **Subsequent event**

The Board of Directors of the Holding Company in its meeting held on 28 February 2025 has approved an interim cash dividend of Rs. Nil per share (31 December 2023: Rs. Nil per share), amounting to Rs. Nil (31 December 2023: Rs. Nil) for the year ending 30 June 2025.

16 Date of authorization for issue

The Board of Directors of the Holding Company	in its meeting held on 2	8 February 2025 has	authorized to
issue these condensed interim consolidated financia	al statements.		

Chief Executive Officer	Chief Financial Officer	Director





